

Tab	Document Description
1	[Proposed] Findings of Fact and Conclusions of Law on Teva Pharmaceuticals USA, Inc.'s Defense and Counterclaim of Inequitable Conduct

**EXHIBITS CITED IN TEVA'S BRIEF AND/OR PROPOSED FINDINGS**

<b>Tab</b>	<b>Trial Exhibit Number</b>	<b>Document Description</b>
2	PTX 13	U.S. Patent No. 4,452,808
3	PTX 35	U.S. Patent No. 4,824,860
4	DDX 10	Inactive '860 Patent Compound
5	DDX 11	Inactive '860 Patent Compound
6	DTX 19	Prosecution History for '860 Patent
7	DTX 22	R. Eden Curriculum Vitae
8	DTX 24	A. Wright Laboratory Notebook, July 2, 1986
9	DTX 28	Draft Project Plan, August 1987
10	DTX 35	Costall, B. and Naylor, R.J., <i>SK&amp;F 101468-A: a centrally acting dopamine agonist having antiparkinson, antidepressant and anxiolytic activity</i> , July 9, 1987
11	DTX 36	Costall, B. and Naylor, R.J., <i>Action of SK&amp;F 101468-A in mice with unilateral 6-OHDA lesions of the substantia nigra</i> , September 1987
12	DTX 37	Costall, B. and Naylor, R.J., <i>Action of SK&amp;F 101468-A in a Model of Parkinson's Disease induced by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the common marmoset</i> , September 1987
13	DTX 41	Teva's Notice of 30(b)(6) Deposition April 5, 2006
14	DTX 45	G. Gallagher Laboratory Notebook
15	DTX 56	DeMarinis, R. et al., <i>Syntheses and In Vitro Evaluation of 4-(2-aminoethyl)-2-3(H)-Indolones and Related Compounds as Peripheral Prejunctional Dopamine Receptor Agonists</i> , 1986
16	DTX 97	D. Owen Declaration and Power of Attorney, May 19, 1988
17	DTX 98	SK&F Project Meeting Minutes May 29, 1986
18	DTX 100	SK&F Project Meeting Minutes October 30, 1986
19	DTX 101	SK&F Project Meeting Minutes July 16, 1986

Tab	Trial Exhibit Number	Document Description
20	DTX 102	SK&F Project Meeting Minutes September 3, 1986
21	DTX 132	Revised Privilege Log of GSK April 18, 2006
22	DTX 133	Giddings, P.J., letter to European Patent Office, November 25, 1991
23	DTX 134	European Patent Office letter to P.J. Giddings, July 26, 1991
24	DTX 136	Second Privilege Log of GSK May 2, 2006
25	DTX 137	Third Privilege Log of GSK May 24, 2006
26	DTX 138	Fourth Privilege Log of GSK May 31, 2006
27	DTX 140	Plaintiff GSK's Responses to Defendant's 1 <sup>st</sup> Set of Interrogatories, October 3, 2005
28	DTX 160	Cannon, J.G., Hsu, F., Long, J.P., Flynn, J.R., Costall, B., and Naylor, R.J., <i>Preparation and Biological Actions of Some Symmetrically N, N-Disubstituted Dopamines</i> , J. Med. Chem., 1978, Vol. 21, No. 3: 248-253
29	DTX 311	Internal Prosecution History for U.S. Patent No. 4,452,808
30	DTX 312	Declaration and Power of Attorney, D. Owen, 1988
31	DTX 375	U.S. Patent 4,206,210
32	DTX 376	Hieble, P. et al., <i>Synthesis and Evaluation of Non-Catechol D-1 and D-2 Dopamine Receptor Agonists: Benzimidazol-2-one, Benzoxazol-2-one, and the Highly Potent Benzothiazol-2-one 7-Ethylamines</i> , J. Med. Chem., 1987

**DEPOSITION TRANSCRIPT EXCERPTS CITED IN TEVA'S BRIEF AND/OR  
PROPOSED FINDINGS**

Tab	Deposition Transcript
33	Excerpts from the deposition of Brenda Costall
34	Excerpts from the deposition of Roger Eden
35	Excerpts from the deposition of Peter Giddings


<b>Tab</b>	<b>Deposition Transcript</b>
36	Excerpts from the deposition of Carol Harvey
37	Excerpts from the deposition of John Long
38	Excerpts from the deposition of David Owen

**PLEADINGS AND CORRESPONDENCE CITED IN TEVA'S BRIEF AND/OR  
PROPOSED FINDINGS**

<b>Tab</b>	<b>Pleadings and/or Correspondence</b>
39	05/30/2006 Letter from M. Gordon to C. Brahma re Discovery Responses

I declare under penalty of perjury that the foregoing is true and correct. Executed in  
Wilmington, Delaware.

Respectfully submitted,

  
\_\_\_\_\_  
Monté T. Squire (No. 4764)

Dated: February 7, 2007

**CERTIFICATE OF SERVICE**

I, Monté T. Squire, Esquire, hereby certify that on February 14, 2007, I caused to be electronically filed a true and correct copy of the foregoing document with the Clerk of the Court using CM/ECF, which will send notification that such filing is available for viewing and downloading to the following counsel of record:

Patricia Smink Rogowski, Esquire  
Connolly, Bove, Lodge & Hutz LLP  
The Nemours Building  
1007 North Orange Street  
Wilmington, DE 19801

I further certify that on February 14, 2007, I caused a copy of the foregoing document to be served by hand delivery on the above-listed counsel of record and the following non-registered participants in the manner indicated:

**BY E-MAIL**

William F. Lee, Esquire  
Wilmer, Cutler, Pickering, Hale and Dorr LLP  
60 State Street  
Boston, MA 02109

Cristina C. Ashworth, Esquire  
Wilmer, Cutler, Pickering, Hale and Dorr LLP  
1875 Pennsylvania Avenue, N.W.  
Washington, DC 20006

YOUNG CONAWAY STARGATT & TAYLOR, LLP

/s/ Monté T. Squire

Monté T. Squire (No. 4764)  
The Brandywine Building  
1000 West Street, 17th Floor  
Wilmington, Delaware 19801  
(302) 571-6600  
msquire@ycst.com

Attorneys for Teva Pharmaceuticals U.S.A., Inc.